[Phase II clinical study of LC9018 on carcinomatous peritonitis of gastric cancer. Subgroup for Carcinomatous Peritonitis, Cooperative, Study Group of LC9018].

Abstract

Using patients with carcinomatous peritonitis caused by gastric cancer, we conducted a Phase II clinical study of LC 9018 by administering the agent alone or in combination with mitomycin C (MMC). Out of 29 patients enrolled, 12 were treated with LC 9018 alone and 17 others with LC 9018 + MMC. Of these, 15 cases were found completely evaluable. The response rate for 15 complete cases against carcinomatous peritonitis was 60.0% (3/5) for the group treated with LC9018 alone and 70.0% (7/10) with LC9018 + MMC. Of the 27 eligible patients, the ascites could be controlled in 58.3% (7/12) for those treated with LC9018 alone and 60.0% (9/15) for those with LC9018 + MMC, with tumor cells being eliminated in 50.0% (6/12) and 60.0% (9/15), respectively. Major adverse reactions included fever, nausea/vomiting, abdominal pain and increases in GOT and GPT. These findings suggest that LC9018 might be a useful therapeutic agent against carcinomatous peritonitis of gastric cancer whether used alone or in combination with MMC.

• Authors: T Okamura, Y Maehara, K Sugimachi
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 16 Issue 6 Pg. 2257-62 (Jun 1989) ISSN: 0385-0684 [Print] Japan
• PMID: 2660750 (Publication Type: Case Reports, Clinical Trial, Comparative Study, Controlled Clinical Trial, English Abstract, Journal Article, Multicenter Study)

Chemical References

• Adjuvants, Immunologic
• LC 9018
• Mitomycins

Topics

• Adjuvants, Immunologic (adverse effects, therapeutic use)
• Adult
• Aged
• Ascites (pathology, therapy)
• Combined Modality Therapy
• Drug Evaluation
• Female
• Fever (etiology)
• Humans
• Japan
• Lacticaseibacillus casei
• Male
• Middle Aged
• Mitomycins (therapeutic use)
• Multicenter Studies as Topic
• Peritonitis (etiology, therapy)
• Remission Induction
• Stomach Neoplasms (complications, pathology)